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Japanese encephalitis is a mosquito-borne encephalitis that occurs in Asia and is caused by 
Japanese encephalitis virus (JEV), a member of the genus Flavivirus. Although many 
flaviviruses can cause encephalitis, JEV causes particularly severe neurological 
manifestations. Despite substantial advances in our understanding of Japanese encephalitis 
from in vitro and animal models, studies of pathogenesis and treatment in humans are 
lagging behind. Few mechanistic studies have been conducted in humans and only four 
clinical trials of therapies for Japanese encephalitis have taken place in the past 10 years, 
despite an estimated incidence of 69,000 cases per year. Previous trials for Japanese 
encephalitis might have been too small to detect important benefits of potential treatments. 
Furthermore, the number of patients needed in a single study to reach statistical significance 
might be greater than the total number of patients with confirmed Japanese encephalitis 
ever randomly assigned in a treatment trial. Many potential treatment targets exist for 
Japanese encephalitis, and pathogenesis and virological studies have uncovered 
mechanisms by which these drugs could work. In this Review, we summarize the 
epidemiology, clinical features, prevention and treatment of Japanese encephalitis, and 
focus on potential new therapeutic strategies that are based on repurposing existing 
compounds that are already suitable for human use and could be trialled without delay. We 
use our newly improved understanding of Japanese encephalitis pathogenesis to posit 
potential treatments, and outline some of the many challenges that remain in tackling the 





• Japanese encephalitis is a severe disease caused by Japanese encephalitis virus, 
genus Flavivirus, family Flaviviridae, which is endemic to most of rural Asia, and for 
which no specific treatment exists 
 
• Japanese encephalitis causes loss of more disability-adjusted life years than does 
any other arthropod-borne virus, owing to the frequent neurological sequelae of the 
condition 
 
• Pathogenesis studies indicate that inhibition of viral replication, viral spread, and the 
host response are needed in combination for optimal therapy  
 
• Animal models and in vitro experiments highlight a number of compounds that are 
potentially suitable for treatment of Japanese encephalitis in humans that could be 
tested without delay 
 
• The minimum clinically significant treatment effect has probably been under-
estimated, and previous clinical trials of Japanese encephalitis have been too small; 




Japanese encephalitis is the most commonly diagnosed epidemic encephalitis in the world, 
and is found throughout South and Southeast Asia, encompassing an area delimited by 
Pakistan to the West, the Philippines and Japan to the East, and the Australian Torres Strait 
Islands in the South. The most comprehensive estimate of incidence within the past decade 
suggests that 69,000 cases of Japanese encephalitis occur every year1. However, other 
estimates vary widely — from 50,000 to 175,000 cases per year — and in reality this number 
can fluctuate with cycles of transmission and is likely to be an underestimate. Japanese 
encephalitis is thought to cause the loss of 709,000 disability-adjusted life years annually2, 
making Japanese encephalitis the foremost arboviral disease of man by this measure, 
ranking above dengue in the 2004 WHO global burden of disease report3, the last time that 
Japanese encephalitis featured as an individual diagnosis in the report. 
 
Japanese encephalitis is caused by Japanese encephalitis virus (JEV), a member of the 
genus Flavivirus, family Flaviviridae, which includes dengue, West Nile, and Zika viruses4. 
Although several members of the genus Flavivirus cause encephalitis, JEV is remarkable in 
the high likelihood and severity of neurological disease that it elicits; by contrast, systemic 
features such as haemorrhage and jaundice are infrequently described for JEV. Over the 
past decade, many advances have been made in our understanding of the biology of the 
virus, yet in the same period only four treatment trials have been conducted into therapies 
for Japanese encephalitis. To date, no trials on Japanese encephalitis have translated into 
improvements in treatment; however, in total, only 381 patients with proven Japanese 
encephalitis have been randomly assigned in treatment trials. Nevertheless, in vitro and 
animal model studies have revealed many drugs that have activity against JEV, which could 
be suitable for use in humans. Studies of pathogenesis and virology have uncovered the 
mechanisms by which these drugs might work and identified potential new strategies for 
Japanese encephalitis treatment, often based on repurposing existing compounds. Here, we 
review basic biological and clinical aspects of the disease, and discuss new advances in our 
understanding of Japanese encephalitis that have highlighted compounds with anti-JEV 
activity in vitro and in animal models, and could be used in humans. In addition, we discuss 
some tentative sample size calculations for Japanese encephalitis treatment trials, using a 
clinical scoring system specifically developed for measurement of outcome from encephalitis 
in field settings such as those were JE is endemic. In this way, we aim to stimulate new 
activity in the field to improve treatments for individuals with Japanese encephalitis. Although 
vaccines for Japanese encephalitis are available, the disease will never be eradicated owing 
to its zoonotic cycle. Moreover, its propensity to cause unpredictable outbreaks in 
unexpected places make vaccination planning challenging, underscoring the need to 
develop treatments for this devastating condition. 
 
 
[H1] Virology and epidemiology 
 
JEV is a single-stranded, positive sense RNA virus5 (FIG. 1) — features that it shares in 
common with other flaviviruses. JEV circulates between wild wading birds in Asia and is 
transmitted by mosquitoes of the genus Culex. Seminal epidemiological studies in Japan in 
the mid-20th century established pigs as amplifying hosts for JEV6,7. However, the 
dominance of pigs as amplifying hosts has been challenged, as countries such as 
Bangladesh that have predominantly Muslim populations and very little pig farming still have 
an appreciable burden of Japanese encephalitis in humans8. In 2017, a complete JEV 
genome was identified by unbiased RNA sequencing in a patient co-infected and clinically 
diagnosed with yellow fever in Cunene province, Angola9, raising the possibility that the 
geographic range of JEV might be greater than previously thought. Non-vector transmission 
of JEV between pigs via respiratory secretions has also been described under experimental 
conditions10, although the relevance of this process to human disease is unclear. 
 
In endemic areas, Japanese encephalitis mostly affects children; however, cases are 
observed in adults when JEV is introduced into areas previously considered non-
endemic11,12, or when non-immune adults are introduced into Japanese encephalitis 
endemic areas13,14. Japanese encephalitis is mostly a rural disease12, although urban and 
peri-urban transmission is also reported15,16. Historically, two patterns of JEV transmission 
were recognised: seasonal epidemic transmission that peaks in late summer in temperate 
regions (23–43º N), and year-round low-level endemic transmission in tropical regions (1–
13º N)17. In reality, outbreaks do occur in tropical regions and between 13–23º N18, but 
cases occur at all times of year and are often under-recognised19. The incidence of 
Japanese encephalitis varies from 0.003 per 100,000 people in areas with established high 
quality vaccination programs, such as Japan and Korea, to 3.7 per 100,000 people in areas 
such as Cambodia, Indonesia and Malaysia1, but these numbers are probably under-
estimates. 
 
Unlike in pigs, no onward transmission occurs from humans because viraemia is insufficient 
to be infectious to the mosquito vector, making humans a dead-end host for JEV. The vast 
majority of JEV infection in humans is asymptomatic or causes an illness so mild as to not 
present to health facilities. An estimated 0.1–1% of JEV infections culminate in 
encephalitis20,21, although, given the estimated annual number of cases (~69,0001) and the 
size of the population at risk (2–3 billion people), the actual risk could be lower. After 
exposure, neutralizing antibody develops22, and disease is not seen in adult populations in 
endemic areas, implying that immunity is lifelong. Episodic re-exposure of individuals to JEV 
probably also aids maintenance of life-long immunity. Consequently, childhood residence in 
areas with an established Japanese encephalitis endemic results in near universal exposure 
and almost all adults in these regions are JEV seropositive23. Immunity is determined by 
subclinical exposure, not by age, although cases can also be observed in old age as 
immunity wanes24. 
 
[H1] Clinical features 
 
JEV infection begins as an undifferentiated febrile illness. This might be the only 
manifestation25, although it is unknown what proportion of JEV infection in humans causes 
self-limiting illness without involvement of the CNS. Patients with encephalitis have usually 
had other non-specific features such as coryza, diarrhoea or rigors. After 3 or 4 days, this is 
followed by the onset of acute encephalitis syndrome, with clouding of consciousness, 
headache, vomiting and often seizures. Focal neurological signs are variable, and can 
reflect the anatomical sites of damage. Parkinsonian features, including mask-like blank 
staring faces (FIG. 2), and tremors reflect involvement of the basal ganglia26; other 
movement disorders include lip-smacking, bruxism, choreoathetosis and hemiballismus. 
Poliomyelitis-like flaccid paralysis indicates damage of anterior horn cells in the spinal 
cord27, and cranial nerve signs include facial palsies, ptosis and abnormalities of eye 
movements. Obvious generalized tonic–clonic seizures can occur, and subtle motor seizures 
can also be observed in some instances, especially in advanced disease28. Features outside 
the brain have also been described, including pulmonary oedema (which can be neurogenic 
as a result of brainstem involvement)13, hepatomegaly, splenomegaly, modestly raised liver 
enzymes and thrombocytopaenia29. When Japanese encephalitis occurs in adults, similar 
signs are seen30. 
 
JEV has occasionally been associated with Guillain Barré syndrome (GBS), which provides 
an interesting parallel with Zika virus-related disease in South America31,32. Patients with 
JEV-associated GBS have shown electrophysiological evidence of demyelination and, 
occasionally, axonal damage, and inflammatory infiltrates of lymphocytes and monocytes 
have also been observed in a fatal case31. A good response to steroids and intravenous 
immunoglobulin was described in one individual32, but the use of plasmapheresis has not 
been reported. JEV can present with flaccid paralysis27 — as can other flaviviruses, 
particularly West Nile virus33 — but this feature arises from the distinct mechanism of 
involvement of the anterior horn cells of the spinal column (in a similar manner to 
poliomyelitis), damage to which can be seen histologically at post mortem34. GBS has also 
been reported in other flavivirus infections, such as dengue35 and West Nile virus36. In the 
single case of GBS attributed to West Nile virus, neuropathy was predominantly 
demyelinating but an axonal component was also present, so anterior horn cell infection is 
difficult to completely rule out in this instance36. Immune mediated transverse myelitis37, 
acute disseminated encephalomyelitis38 and N-methyl-D-aspartate (NMDA) receptor 
encephalitis39 have also been reported following JEV infection. Although JEV can impair 
neurogenesis in experimental systems40, the few reports that exist of human infection in 
pregnancy describe either abortion (with virus isolated from fetal CNS in one case) or normal 
delivery41,42. Infection of pregnant sows also causes abortion and can be a major threat to 
pig farming43. JEV has not been associated with microcephaly as Zika virus has in South 
America. The mechanisms behind this difference are as yet unknown, but the fact that 
Japanese encephalitis predominantly affects children in endemic areas might provide one 
explanation. 
 
JEV is one of many causes of an acute encephalitis syndrome in which patients present with 
impaired consciousness; as such, diagnosis of Japanese encephalitis requires laboratory 
confirmation. Abnormalities of routine peripheral blood tests of patients with Japanese 
encephalitis are non-specific; neutrophilia is common and hyponatraemia can be present. 
Analysis of cerebrospinal fluid (CSF) typically shows a lymphocytic pleocytosis, but CSF can 
be acellular in some cases28,44,45. Diagnosis of Japanese encephalitis is confirmed by 
demonstration of JEV-specific IgM in CSF by ELISA, which is present in nearly all patients 
by day 7 of illness46. Repeat lumbar puncture can be necessary if early testing is negative 
and the diagnosis needs to be confirmed; in practice, during outbreaks, this confirmation is 
rarely needed if many patients have already tested positive. If CSF is unavailable, serum 
testing should be interpreted with caution in areas co-endemic for other flaviviruses, such as 
dengue virus, and neutralisation assays for both JEV and co-circulating viruses might be 
necessary. Viral nucleic acids and infectious virus can also be found in CSF but much less 
frequently than JEV-specific IgM 47,48. Unlike many other members of the Flavivirus genus, 
JEV is very infrequently isolated or detected by reverse transcription PCR (RT-PCR) from 
blood during acute illness, although it has been isolated from clot-derived white blood cells 
after co-culture with healthy donor peripheral blood mononuclear cells (PBMCs)49. JEV also 
cannot be detected in urine by RT-PCR50. Many imaging findings are described in patients 
with Japanese encephalitis51, but diagnostic utility has only been assessed for hypodense 
lesions in the thalami on CT (FIG. 2). The sensitivity of this finding is only 22% in a 
Japanese encephalitis endemic area, and thalamic hypodensities are also found in most 
other flaviviral encephalitides — as such, these features must be interpreted in the 
geographical context52.  
 
The reported outcomes of Japanese encephalitis vary widely, with mortality ranging from 
around 5% to 50% 14,19,24,28,29,42,44,53-85; the neurological sequelae observed are dependent in 
part on the duration of follow up66. The average mortality in studies published over the past 
30 years is 18% (95% CI 14–21%; FIG. 3a). Over the same period, the proportion of 
individuals who survive but do not experience a full neurological recovery is 44% (95% CI 
35–53%), meaning that just over half of patients who develop clinical Japanese encephalitis 
do not recover completely. 
 
[H3] Latency. Although Japanese encephalitis is a typical acute infection, with a clinical 
course lasting 2–3 weeks12, some evidence shows that virus can persist in the nervous 
system86 and PBMCs87 for 4–8 months after illness onset. This phenomenon seems to be 
rare in individuals with Japanese encephalitis, with few published reports in humans. There 
is some evidence for latent JEV infection in mice88, and West Nile virus RNA has been 
identified in urine of individuals infected with this pathogen many years after initial illness89, 
so the phenomenon might not be confined to JEV. JEV-infected microglial and neuronal 
mouse cell lines can produce infectious virus for many weeks90,91, and human monocytes 
have also been shown to produce JEV for weeks92, providing a possible cellular basis for 
persistent infection. However, the consequences of this finding in living patients remains 
unknown, and persistent infection does not seem to be a common issue in clinical practice. 
 
[H1] Genotype and geographic spread  
 
JEV can be divided into five genotypes, all of which can be traced back to a common 
ancestor that probably emerged in the region of modern-day Indonesia and Malaysia in 
Southeast Asia (FIG. 5a)93,94. Early isolates from the 1930s to the 1950s of JEV were all 
genotype III. However, genotype I JEV is gradually replacing genotype III (FIG. 5b)95, 
although most human cases are still genotype III (FIG. 5c)96. JEV genotype I is better 
adapted than genotype III to the mosquito vector, with a shorter extrinsic incubation time97; 
but this adaptation comes at the cost of a narrower host range96. Climate might also have an 
effect on genotype distribution, as genotypes Ia, II and IV tend to be found in tropical Asia, 
and genotypes Ib and III in temperate Asia94 — although genotype III has also been isolated 
in many tropical areas. 
 
JEV continues to spread and reach new populations. For example, JEV reached the 
Australian Torres Strait islands in 199511; molecular characterisation of the virus in this 
setting revealed that it belonged to genotype II98. Rare Japanese encephalitis cases 
continued to occur in this area over the next few years, including one on the Australian 
mainland99, where JEV was also isolated from mosquitoes100. Since this time, Japanese 
encephalitis cases in this region have abated, and although there have been subsequent 
intermittent isolations of JEV, no human cases of Japanese encephalitis have been reported 
in Australia or the outer islands since 1998101. Why JEV has not become more firmly 
established in Northern Australia and the outer islands is not clear, as the ecological 
conditions are similar to many regions where JEV is endemic. The presence of mosquitoes 
that have a tendency to feed on vertebrates that do not become highly viraemic following 
JEV infection is one potential explanation101. 
 
Many regions of the world also have conditions that seem to be appropriate for JEV, yet no 
circulation of the virus. The related flaviviruses St Louis encephalitis virus and West Nile 
virus both circulate in the USA, which has given rise to concern around the potential for 
introduction of JEV in this region102. Parts of Southern Europe also have suitable conditions 
for JEV, and nucleic acid sequences that seem to correspond to parts of the JEV genome 
have been detected in birds103 and mosquitoes104 in Italy. However, the sequences identified 
were very short (only 167 and 215 base pairs), full length viral genome or infectious virus 
has not been isolated, and no evidence of human infection has been reported105. 
Consequently, emergence of JEV in Italy seems improbable, thus far. West Nile and Usutu 
viruses circulate in the same region, so ongoing flavivirus surveillance could be expected to 
detect JEV if it does emerge. JEV has always been thought to be exclusively transmitted by 
mosquitoes, which affects its potential geographic range. However, the detection of vector 
free transmission via respiratory secretions in pigs10 indicates that a JEV reservoir could be 
maintained in temperate locations with short mosquito seasons. How JEV is maintained in 
more Northern, temperate endemic areas is not known; JEV might persist over-winter in 
mosquitoes, or in lizards, frogs or snakes, or could be re-introduced in migrating birds101. 
The ecology and geographic expansion of JEV is reviewed in more detail elseswhere101. 
 
[H1] Japanese encephalitis vaccination 
 
Several different vaccines have been used to control Japanese encephalitis since the 
1950s106 (TABLE 1, reviewed in ref 69). Early isolates of JEV, which were the foundation of 
vaccine development, were all genotype III. Randomised controlled trials have shown the 
efficacy of vaccination against Japanese encephalitis, and showed that neutralising antibody 
correlated with protection53. Early Japanese encephalitis vaccines were mostly derived from 
mouse brain, but this manufacturing method has now been replaced owing to safety 
concerns and relatively poor immunogenicity in humans 106. The Japanese encephalitis 
vaccines that are most commonly used today are all based on the attenuated strain SA14-
14-2 that was derived from JEV SA14 strain (which itself has fairly low pathogenicity107) 
grown from a pool of Culex pipiens larvae from Xi’an in 1954. The live attenuated Japanese 
encephalitis vaccine SA14-14-2 generates neutralising antibody against wild genotype III 
strains (Beijing-1 and SA14) in humans108-111 but has not been tested against genotype I 
strains. Inactivated, adjuvanted SA14-14-2 (marketed in Europe and North America as 
IXIARO and in Australasia as JE-SPECT) induces neutralising antibody to JEV genotypes I–
IV and gives similar seroconversion rates for genotype I and III viruses112,113, although titres 
against genotype I tend to be lower than those for genotype III. In the past few years, a new 
vaccine has been developed based on an Indian genotype III strain, Kolar-821564XY 
(TABLE 1). This Japanese encephalitis vaccine, JENVAC, also induces neutralising 
antibody against genotypes I–IV114. Whether protection induced by a genotype III vaccine 
will be as durable for genotype I remains to be seen, as genotype I disease has been 
reported to occur after incomplete genotype III vaccination115. Moreover, JEV genotype V is 
also emerging116, although cases in humans are rare. Current vaccines might not be as 
protective against genotype V as other genotypes, although this notion is based on a small 
sample thus far117. 
 
Vaccine use has resulted in a decrease in Japanese encephalitis incidence in many Asian 
countries118,119, but estimates suggest that 80% of cases still occur in areas with established 
Japanese encephalitis vaccination programs1. Why so many cases occur despite 
vaccination is not clear; possible explanations are a lack of vaccine coverage, a lack of 
vaccine effectiveness, or presence of waning immunity in areas where JEV circulation is 
intermittent. In 2006, India — which, along with China, accounts for much of Japanese 
encephalitis disease burden — introduced the live Japanese encephalitis vaccine SA14-14-
2, and a small case control study in Lucknow (Uttar Pradesh, North India) showed a 6-month 
vaccine efficacy of 94.5%120. However, post-marketing studies suggest a lower efficacy121, 
and although cases reported to the National Vector Borne Disease Control Program of India 
(NVBDCP) decreased after vaccine introduction, they have since begun to rise again 
(http://nvbdcp.gov.in/je-new.html). Several sources have documented lower seroconversion 
rates to Japanese encephalitis vaccine SA14-14-2 in India, from 58% to 74%114,121,122, 
compared with studies undertaken outside India. However, clear examples can be found of 
circumstances where serum concentrations of neutralising antibody to contemporary strains 
have waned to undetectable levels in most of the population, yet a sustained reduction has 
been observed in the incidence of Japanese encephalitis123. Consistent with these findings is 
the observation that priming of memory B cells in mice is protective in the absence of serum 
neutralising antibody124. What accounts for the low seroconversion rate of Japanese 
encephalitis vaccine SA14-14-2 in India and whether this finding has clinical importance 
remain unknown. Interference by dengue virus in India has been hypothesized to interfere 
with SA14-14-2 immunogenicity122. 
 
Whatever the reasons for the continued existence of Japanese encephalitis cases in 
endemic areas — whether vaccine failure or failure to administer vaccine — Japanese 
encephalitis remains a major problem in Asia. Although efforts to prevent Japanese 
encephalitis undoubtedly need to be strengthened, the continued occurrence of clinical 
disease despite vaccination campaigns highlights the need to develop new treatments and 
to improve the care of the patients who contract the disease. 
 
[H1] Pathogenesis and therapeutic targets 
 
[H3] Pathogenesis. Despite substantial advances in the past few years, much remains to 
be learned about the pathogenesis of Japanese encephalitis (FIG. 6a). Studies in mouse 
models have characterised the initial pathogenesis of JEV infection: after peripheral 
inoculation with JEV, a round of replication occurs in the local lymph nodes125, and virus can 
be found peripherally in monocytes and some T cells126. The initial replication is then 
followed by viraemia and the spread of infection to the CNS (FIG. 6b). JEV replicates well in 
monocytes92,127 and dendritic cell lineages127-130 from humans and mice, although replication 
in human neuronal cell lines is much more efficient92. JEV probably infects cells of the 
macrophage and dendritic cell lineage in the skin — in an analogous fashion to dengue 
virus131 — with the infected cells then carried to local lymph nodes from where viraemia and 
then CNS infection can occur, if replication is sufficient125. The incubation period of JEV in 
mice is around 5 days, whereas the incubation period after intranasal inoculation of JEV in 
macaques is 7–10 days132. In humans, the incubation period is often described as 5–15 
days; however, published data describing the incubation period in humans are scant, and 
they suggest a median of around 8.4 days, similar to the macaque model133. 
 
Spread of JEV to the CNS can be prevented by neutralising antibody, which alone is 
sufficient to prevent encephalitis134 (FIG. 6a). The importance of antibody in protection from 
JEV infection is highlighted by the observation that mice lacking B cells are extremely 
sensitive to JEV infection135, and priming136 or adoptive transfer124 of JEV immune memory B 
cells is protective even in the absence of pre-challenge neutralising antibody. 
 
[H3] Entry into the CNS. The mechanism by which JEV enters into the brain remains 
elusive. The observations of peripheral replication and viraemia in animal models, along with 
the distribution of lesions in the brain125,137, strongly suggest that JEV enters the CNS from 
the blood. JEV antigen is detected in the vascular endothelium in vivo137-139, but whether this 
observation reflects actual replication is unknown: a ‘Trojan horse’ mechanism of CNS entry 
via an infected leucocyte cannot be discounted completely 49,87,126. 
 
The effect of JEV infection on the blood–brain barrier (BBB) has been studied mostly in 
mouse models of Japanese Encephalitis. JEV is not a natural pathogen of mice, which are in 
general resistant to disease, unless JEV is inoculated when the mice are very young, or via 
the intracerebral route. Although there is substantial variation between laboratories in this 
regard, using a model where JEV is pathogenic and produces encephalitis in the infected 
mice, BBB breakdown can be readily demonstrated,140. The mechanism is uncertain, with 
some evidence it may be induced by soluble mediators, possibly interleukin (IL)-8141. 
However, BBB breakdown seems to be a consequence rather than the cause of JEV 
infection of the brain142 and, although it contributes to pathology, is not absolutely required 
for virus entry into the CNS. 
 
[H3] CNS pathology and inflammation. Although JEV can replicate in many cell types in 
vitro, inside the CNS its principle target cells are neurons 137-139,143. In the macaque model of 
Japanese encephalitis, JEV antigen is also found in microglia and occasionally in blood-
derived macrophages143. Marked inflammation is present in the brain of patients with 
Japanese encephalitis — a phenomenon that might be amenable to treatment. Inflammatory 
infiltrates in the brains of humans infected with JEV have not been very well characterised, 
but are dominated by T cells and, to a lesser extent, by monocytes and macrophages137.  
 
Reports of the composition of T cells in inflammatory infiltrates in the brains of people with 
Japanese encephalitis have been inconsistent. CD4+ T cells predominantly were observed 
at post mortem in seven children who died from Japanese encephalitis138, but CD8+ T cells 
were most prevalent in two adult fatal cases144. CD4+ T cells were also found to be enriched 
in the CSF of 15 children infected with JEV 145, although the small number of cases makes it 
difficult to draw a firm conclusion that the T cell infiltrates in adults and children are different. 
Histologically, fatal cases of Japanese encephalitis in humans are characterised by 
perivascular cuffing and vascular leakage, sometimes with small haemorrhages, and small 
areas of well demarcated (‘punched out’) focal necrosis137,138,146. Viral antigen is found in 
inflamed areas of brain, but is also seen in non-inflamed areas of brain132,146. Because JEV 
spreads to the brain via the blood, and viraemia is so transient and hard to demonstrate in 
humans, it is likely these non-inflamed brain regions represent areas that are affected by 
JEV later in the disease process by contiguous or axonal spread of the virus 139, which 
suggests that a therapy that blocks viral spread might limit damage to the CNS. 
Alternatively, this may represent viral protein spread by axonal transport, with no active 
replication in the non-inflamed areas. Ultimately, neurons probably die through a 
combination of direct viral-mediated damage, immune-mediated damage (see later in the 
article) and apoptosis, which together give rise to the clinical symptoms of the condition. 
Features of raised intracranial pressure are reported in both clinical and pathological studies 
of Japanese ecephalitis28,138,139, indicating that measures to reduce this pressure might also 
be beneficial. 
 
Several lines of evidence support a pathological role for CNS inflammation in patients with 
Japanese encephalitis. In animal models of Japanese encephalitis, the BBB breaks down, 
which results in a large influx of monocytes and lymphocytes into the brain147-149. Consistent 
with pathological findings in fatal cases of Japanese encephalitis in humans and in animal 
models of the disease, high levels of inflammatory mediators can be detected in CSF of 
patients infected with JEV, and increasing concentrations of TNFα and IL-6 correlate with 
poor outcome in these individuals 150,151. Blockade of TNF with Etanercept reduces 
inflammation and improves survival in JEV-infected mice152, and manipulation of pro-
inflammatory responses by other means — such as genetic ablation of toll-like receptor 
(TLR)4 — protects mice against the lethal effects of Japanese encephalitis147. Generally, 
mice that survive acute JEV infection in these models (typically mice that are not affected or 
have recovered approximately three weeks into the experiment) show strong type I 
interferon (IFN) responses, which result in a greater restriction of viral replication, less 
uncontrolled inflammation in the CNS, and enhanced resistance to JEV. However, treatment 
with IFNα did not affect outcome from Japanese encephalitis when it was tested in a clinical 
trial59. 
 
[H3] Adaptive immunity and immunopathogenesis. Although the role of antibodies in 
protection against Japanese encephalitis is well established, the role of T cells, both in 
protection and pathology, is less well established. Evidence for a protective role by T cells in 
mouse models of Japanese encephalitis is contradictory, with some investigators finding no 
role for T cells136, some finding a partially protective role135,153 and still others finding 
complete protection154,155. In one mouse model of the disease, depletion of CD8+ T cells 
resulted in a 100-fold increase in virus in the CNS, whereas mice that did not undergo T cell 
depletion had high levels of IFNγ+ CD8+ T cells in brain 135. These pivotal experiments could 
explain some of the observed differences between mouse models, but — more importantly 
— they suggest that either anti-viral or anti-inflammatory therapies alone might not be 
maximally effective, and that studies of combination therapies aimed at suppressing both 
virus replication and pathologic host responses together should be investigated. Some 
evidence also supports this paradoxical role of host immunity in humans: memory T cell 
responses in individuals who were asymptomatic after JEV exposure were found to be 
predominantly CD8+ and were highly cross-reactive whereas in individuals who had 
recovered from Japanese encephalitis T cell responses were mostly CD4+ and not cross-
reactive156. Among individuals who had recovered from Japanese encephalitis, the quality of 
the T cell response correlated with the clinical outcome, and responses dominated by CD4+ 
T cells that produce TNFα alone, and not IFNγ or IL2 were associated with incomplete 
recovery (FIG. 7). This observation, together with the observation that most of the T cells 
found in brain and CSF in patients with Japanese encephalitis are CD4+138,145, supports the 
notion that CD4+ T cells are pathogenic in this disease. Taken together, these results 
suggest that immunity is effective if JEV can be contained in the periphery, but once inside 
the CNS, prevention of virus-induced damage comes at the cost of substantial immune-




Given the potential severity of Japanese encephalitis, and its potential to emerge in 
previously non-endemic areas, the lack of work done to test treatments for this disease is 
surprising. To date, no specific treatment for Japanese encephalitis has been shown to 
work. However, supportive management is beneficial in patients with Japanese encephalitis, 
and several complications of the disease that increase risk of death are treatable. For 
example, the presence of seizures, which are associated with raised intracranial pressure28, 
indicates a poor prognosis, and prognosis is worse still in the presence of intractable 
seizures or status epilepticus28,66. Seizure activity, which can be subtle, should be actively 
sought out and aggressively treated, and some observational evidence supports the use of 
routine sedation to improve outcome60. Despite the fact that a clinical trial of high dose (0.6 
mg/kg) dexamethasone given to all patients with suspected Japanese encephalitis did not 
show a benefit56, agents such as corticosteroids or mannitol are nevertheless commonly 
administered to patients with Japanese encephalitis who have intractable seizures or other 
signs of raised intracranial pressure. Although the trial of dexamethasone in patients with 
Japanese encephalitis showed this treatment to be safe, several prominent examples of 
commonly used treatments for other disorders have been shown to be harmful when studied 
systematically — such as bolus fluids in children with shock in a malaria endemic area157. 
This finding further underlines the need for more definitive evidence to validate the use of 
common supportive therapies in Japanese encephalitis. 
 
Other complications, particularly those associated with immobility such as pressure sores 
and contractures, should be prevented by good nursing care. However, this care often falls 
to the family in some areas endemic for Japanese encephalitis. Care should be taken to 
maintain fluid balance and avoid both under-hydration and over-hydration in patients with the 
disease44,60. In unconscious patients, clinicians should be vigilant for aspiration pneumonia, 
which should be treated upon early clinical suspicion. In practice, many patients who present 
with fever and altered consciousness are treated with broad spectrum antibiotics, as 
uncertainty often exists regarding the presence of bacterial infection such as meningitis or 
brain abscess. However, routine antibiotics are not necessary in Japanese encephalitis, so if 
the diagnosis of Japanese encephalitis is secure or strongly suspected, and CSF analysis or 
imaging does not suggest bacterial infection, then antibiotics need not be used. 
 
[H3] Clinical trials in Japanese encephalitis. To date, few randomised clinical trials have 
tested treatments for Japanese encephalitis (TABLE 2). Replication of JEV is inhibited in 
vitro by type I interferon and ribavirin, but neither agent, when tested alone, altered the 
outcome in patients with Japanese encephalitis59,62. High dose dexamethasone did not affect 
the outcome from Japanese encephalitis (see previous discussion)56, but this trial was small 
and underpowered. A preliminary study of intravenous immunoglobulin given for virus-
neutralising and anti-inflammatory effects showed that this approach was safe and feasible, 
but the study was also not powered to detect an improvement in outcome45. However, the 
study showed enhancement of the antibody response to JEV from intravenous 
immunoglobulin treatment, at least in some individuals, a well described phenomenon in 
animal models of Japanese encephalitis158. Lastly, two studies of minocycline — one in 
acute encephalitis syndrome of any cause (hypothesised to improve BBB integrity) and one 
in Japanese encephalitis — recruited only 29 and 44 patients with Japanese encephalitis 
respectively and so, again, were underpowered159,160. 
 
[H1] Existing compounds as therapies  
 
None of the trials on Japanese encephalitis to date have demonstrated a benefit; however, 
many approaches remain untested. Numerous compounds are available that have anti-JEV 
activity (reviewed elsewhere161), including several that have already been used in humans 
for other indications162 (TABLE 3). All of the compounds in TABLE 3 that have direct 
evidence of anti-JEV activity — except for arctigenin163 and clinidipine164 — have been used 
in clinical trials in children, or are in routine use in children. 
 
Most of the therapies for Japanese encephalitis that were previously tested in mouse models 
were administered at the time of or shortly after JEV infection165,166. The exceptions are an 
anti-JEV monoclonal antibody, which was partially protective when given on day 5 after 
infection, at which time JEV was detectable in brain134; minocycline, which was effective 
after symptom onset167; and etanercept (a recombinant fusion protein of TNF receptor to 
IgG1), which was administered at days 3 and 5 after infection152 (TABLE 3). Fenofibrate was 
only effective if administered several days before JEV infection168 and so is unsuitable for 
clinical testing — although useful mechanistic information about the disease might be 
learned from this agent. Pentoxifylline has been studied as an adjunctive treatment both for 
malaria and dengue fever because of its anti-TNF activity169,170, but it also inhibits JEV 
replication in vitro and has protective effects in mouse models of Japanese encephalitis171. 
The pathological role of TNF in Japanese encephalitis is further supported by the protective 
effect of direct TNF blockade with etanercept, as well observations that link high levels of 
TNF with poor outcome in humans with the disease150,156. Although etanercept improved 
survival of JEV infected mice and reduced neruoinflammation, JEV replication was 
marginally increased152. 
 
As described previously in the article, some mouse studies demonstrate that animals with 
intact immune systems die with uncontrolled inflammation after JEV infection, whereas those 
with impaired immunity — for example, depletion of CD8+ T cells — die with less 
inflammation but a much higher viral burden135. This finding implies that targeting viral 
replication and inflammation concurrently may have a synergistic effect, which might be 
achieved using the available agents in TABLE 3, or using combinations of agents that have 
already been tested, such as steroids, ribavirin and interferon; however, this strategy has not 
yet been attempted in humans. 
 
Lastly, a theoretic basis supports a benefit for some other drugs in Japanese encephalitis 
and thus these agents merit testing, at least in an animal model of the disease (TABLE 3). 
Knockout of Tlr4 protects mice against the lethal effects of Japanese encephalitis, and so 
this receptor represents a potential therapeutic target147. TLR4 is antagonised by eritoran, 
which has been used in phase III trials for sepsis and has also been shown to protect mice 
in a model of influenza172. Recruitment of inflammatory monocytes into the brain can be 
prevented by blockade of the interaction between integrin α4β1 and vascular cell adhesion 
protein 1, which represents the mechanism of action of the multiple sclerosis treatment 
natalizumab. Blockade of this pathway also partly protects mice from lethal West Nile 
infection173. Inhibition of c-Jun N terminal kinase (JNK1; also known as mitogen-activated 
protein kinase 8) reduced neuroinflammation, viral load and mortality in a mouse model of 
Japanese encephalitis174; consequently, JNK1 is a potential drug target in humans, but 
different compounds would be required to those used in mice. High IL-6 levels in CSF 
correlate with mortality in humans151, so the anti-IL6 antibody tocilizumab might also have 
therapeutic potential in patients with Japanese encephalitis. 
 
[H1] Considerations for new treatment trials 
 
Most treatment trials in patients with Japanese encephalitis have been designed to show an 
absolute reduction in mortality or improvement in outcome of around 20–25%, which 
translates into a relative reduction in mortality (or poor outcome) of greater than 50% in most 
cases — a large effect. The sample sizes of humans with Japanese encephalitis have been 
modest, ranging from 44 to 153 patients per study, with an overall total of only 381 patients 
with confirmed Japanese encephalitis ever to be recruited into randomised treatment trials 
(TABLE 3).  
 
An alternative approach that could enable the detection of a smaller effect size than in 
existing trials, would be to use a linear outcome measure, such as an outcome score, 
instead of a categorical good/bad outcome. Whilst many scoring systems exist to measure 
neurological disability and outcome after various types of neurological injury, few have been 
developed specifically for encephalitis, and fewer still have been validated in the setting 
where Japanese encephalitis occurs. The Liverpool outcome score (LOS) is a simple 
numerical scoring system that has been developed and applied to patients with Japanese 
encephalitis as well as other forms of encephalitis across different age groups and 
cultures63,64,156,175 . This score classifies outcomes as complete recovery (V), recovery with 
sequelae but with the (age appropriate) ability to live independently (IV), recovery with 
disability precluding independent living (III), fully dependent for daily activities (II) and death 
(I). The score is easy to use and is suitable for use in the field, an important consideration for 
Japanese encephalitis trials. An increase of one point on this scale represents a clinically 
meaningful improvement. 
 
Four studies have been conducted using the LOS63,64,156,175, we estimate that 38% of 
patients in these studies have a poor outcome, defined as death or neurological sequelae 
sufficiently bad to preclude independent living (assuming an 18% mortality (FIG. 4) in those 
studies that recruited only follow up cases). An average improvement of one point on the 
LOS scale would result in a reduction in the proportion of patients with poor outcome to 
27%. For a trial to have 80% power to show this difference at 5% significance level would 
require 569 patients to be recruited (assuming 10% loss to follow up). Treating the LOS as a 
continuous variable (which, strictly speaking, it is not) could allow the sample size to be 
reduced to 356. Although this number is likely an under-estimate, due to the ordinal 
categorical nature of the LOS (a patient cannot have an outcome score of 3.5), it is highly 
likely that the number of patients needed to show clinically meaningful benefit would reduce 
from 569 (the number needed to show improvement in a categorical outcome measure). The 
real figure will lie somewhere in the range 356 to 569, but all scenarios would still require 
approximately the same number of patients, or more, with confirmed Japanese encephalitis 
in a single treatment trial than have ever been randomised.  
 
The choice of follow-up time point also requires careful consideration; an end-point reached 
during the in-patient stay may have less loss to follow up, as trial participants are relatively 
“captive” in fixed locations, but follow-up of three to six months gives a more accurate picture 
of the real clinical outcome66, though is challenging in the rural settings where JE occurs. 
Assessment of combinations of therapies, including supportive measures, perhaps using 
factorial design, will make trial design more complex still. Consequently, it is easy to see 
how the existing studies on treatment of Japanese encephalitis have not been sufficient to 




Japanese encephalitis remains a devastating disease with no specific treatment other than 
best supportive care. Despite the availability of vaccines, 69,000 cases of the disease are 
estimated to occur every year in Asia, and this figure probably represents an under-estimate. 
However, developments in our understanding of Japanese encephalitis within the past few 
years point to several potential avenues of treatment. Several compounds that are already 
approved for human use could be tested without delay. Such trials should be larger than 
previous studies, and will almost certainly need to be multi-centre. Recruitment of individuals 
with Japanese encephalitis can be challenging as many other conditions mimic the disease 
and outbreaks are unpredictable and can occur in remote and resource-limited settings. For 
a successful trial, sufficient infrastructure for good quality diagnostics is needed to ensure 
confirmation of every case. Given the apparently paradoxical role of the immune system in 
Japanese encephalitis, with evidence of both protective and pathological elements, strong 
consideration should be given to trials of combination therapy that test treatment regimens 
comprising both anti-inflammatory and anti-viral drugs. Some potential treatments, such as a 
JEV-specific monoclonal antibody, might provide a clinical proof of principle — if successful 
—to develop treatments for other arboviral encephalitides, and could speed up the 
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Figure 1 | JEV Structure. a | The structure of the Japanese encephalitis virus (JEV) virion 
solved by cryo-electron microscopy (from Wang et al.178, with permission). The JEV virion is 
~50 nm in diameter and contains a central nucleocapsid core of viral RNA and core (capsid) 
protein. In the mature virion, this core is surrounded by a lipid bilayer envelope in which the 
viral membrane and envelope proteins are embedded4. b | The structure of JEV solved by X-
ray crystallography of the envelope protein (from Luca et al.177, with permission). As with 
other flaviviruses, the outer surface of the mature JEV virion is smooth and consists of 180 
copies of envelope and membrane protein, with the envelope proteins arranged as 90 head-
to-tail homodimers in an icosahedron, symmetry T = 3177,178. c | JEV genome organization. 
The JEV genome is 11 kb of single-stranded positive sense RNA, comprising a single 10.7 
kb open reading frame (ORF) flanked by 5’ and 3’ untranslated regions, which function in 
replication. At the 5’ end of the ORF are the core (C, encoding the capsid), pre-membrane 
(prM) and envelope (E) proteins, which together make up the viral particle and are referred 
to as structural proteins. The remaining non-structural (NS) proteins are expressed during 
replication. 
 
Figure 2 | Features of Japanese encephalitis. a | The typical blank staring facial 
expression of an individual with Japanese encephalitis is shown. Reproduced from Solomon 
et al. 2000179 with permission. b | CT scan in an individual with Japanese encephalitis. 
Bilateral thalamic hypodensity in a 7-year-old child in Ho Chi Minh City, Vietnam is illustrated 
(white arrows). In this setting, this finding has a sensitivity of 22% and specificity of 100% for 
a diagnosis of Japanese encephalitis52. However, this feature is also seen in other flaviviral 
encephalitides, so interpretation needs to take account of the local epidemiology. 
(Reproduced from Dung et al. 2009 figure 2a52 with permission.) 
 
Figure 3 | Clinical outcome of Japanese encephalitis. Forest plots showing mortality (part 
a) and proportion of patients with neurological sequelae (part b) from studies of individuals 
with Japanese encephalitis published in the past 30 years.  
 
Figure 4 | Origin and genotype spread of JEV in Southeast Asia. a | Japanese 
encephalitis virus (JEV) probably originated in the region of Indonesia and Malaysia before 
spreading across Asia. Adapted from Solomon et al. 200393 with permission. b | Relative 
proportion of JEV genotypes I and III isolated from any source (humans, other mammals, 
birds and mosquitoes) according to decade of collection c | Number of JEV isolates from 
humans over time. Adapted from Han et al. 201496 with permission. Blue dotted line 
represents JEV genotype I; red solid line represents JEV genotype III. 
 
Figure 5 | Overview of the pathogenesis of Japanese encephalitis. a | After inoculation 
into the skin, virus is thought to replicate in Langerhans dendritic cells (as observed for 
dengue virus131) and/or in keratinocytes (as observed for West Nile virus). Japanese 
encephalitis virus (JEV) is then carried to the local lymph node where further replication 
takes place125. Viraemia occurs and the virus crosses the blood-brain barrier and enters the 
CNS. Major outstanding questions (indicated by “?”) include: which are the true target cells 
for JEV in the skin; is there any role for the CD8+ T cell or antibody response in the early 
stages before viraemia; is there any mechanism other than viraemia to gain entry to the 
CNS; how does JEV get across the blood-brain barrier; and which immune components are 
protective or pathogenic once inside the brain? Circled minus symbols indicate potential 
immune effects that restrict viral replication and/or spread. Modified from Turtle et al. 2012176 
with permission. b | Viral load of JEV after peripheral subcutaneous inoculation with 101.5 
LD50 of JEV Beijing strain into mice. The data show that viral replication is controlled at the 
site of inoculation and in the blood, but once virus enters the CNS unrestricted multiplication 
occurs125.  
 
Figure 6 | CD4+ T cell responses in patients recovered from Japanese encephalitis. a | 
Overall, IFNγ responses are modestly smaller in patients with incomplete recovery from 
Japanese encephalitis and residual neurological disability (poor outcome) than in those who 
recover completely (good outcome). b | TNFα responses are not significantly different 
between individuals who have a poor outcome and those who have a good outcome. c | The 
balance of cytokines produced by CD4+ T cells is different between patients who have a 
poor or a good outcome, with responses in the poor outcome group dominated by TNFα 
single producing cells, whereas responses in the good outcome group are biased towards 
CD4+ T cells that make IFNγ, IL2 and TNFα (so called “polyfunctional” T cells).  Reproduced 
from Turtle at al. 2016156. 
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Table 1. Vaccines against Japanese encephalitis. The early, mouse-brain-derived 
vaccines against Japanese encephalitis are no longer in use owing to concerns regarding 
adverse events including acute disseminated encephalomyelitis (ADEM) — although the 
incidence of ADEM after vaccination was never accurately estimated. The virus strains used 
in vaccine development are all genotype III. Of the currently used inactivated vaccines for 
Japanese encephalitis, most are made for domestic markets and not sold internationally. 
The exception is IXIARO (known as JE-SPECT in Australia and New Zealand), which is 
licensed in Europe, North America and many other countries. IXIARO is the principle 
vaccine used for prevention of Japanese encephalitis in travelers. In areas endemic for 
Japanese encephalitis, the most commonly used vaccine now is the Chinese live attenuated 
vaccine, SA14-14-2, which has been studied extensively in China and other countries, and 
which was WHO pre-qualified in 2013. IXIARO is made from inactivated Japanese 
encephalitis virus (JEV) SA14-14-2, which was chosen for ease of production as it does not 
require containment level 3 facilities. Imojev, the first recombinant vaccine licensed, is based 
on the yellow fever 17D vaccine with the pre-M and envelope genes replaced by those of 
JEV SA14-14-2. The same technology was used to develop the first licensed dengue 
vaccine, Dengvaxia.  
 























followed by 0.2 
mg/kg q6h for 5 
days 
65 55 Death at 
25 days 
Dexamthasone: 
6 of 24 died; 
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mg/kg daily for 7 
days 
153 153 Early 
death (in 
hospital) 
Ribavirin: 19 of 
70 died; 










400 mg/kg daily 
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mg/kg daily (age 
<12) or 200 mg 
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of 13 died; 








mg/kg daily in 
two divided 
doses for 10 days 
44 44 Not stated Minocycline: 2 
of 22 died; 
placebo 5 of 22 
died 
No 
Total number of patients 
randomly assigned to treatment 
677 381 - - - 
 
 
Table 2 | Randomized clinical trials of treatments for Japanese encephalitis. Five 
studies have tested treatments for Japanese encephalitis and one study159 tested 
minocycline for acute encephalitis syndrome and included patients with Japanese 
encephalitis. Minocycline has also been studied in patients with Japanese encephalitis 
alone, though this study was underpowered160. None of these studies showed a detectable 




Compound Evidence and comments References 
Compounds protective against Japanese encephalitis in animal models 
Anti-JEV monoclonal 
antibody (503) 
82% of mice protected with 200 μg/mouse 
antibody given 5 days post infection, when 
virus is detected in the brain. 
Kimura-Kuroda & 
Yasui 1988 (Ref. 134) 
Rosmarinic acid  80% of mice protected by 25 mg/kg from 
day 1 post-infection. 
Swarup et al. 2007 
(Ref. 166) 
Minocycline  70% of mice protected at 90 mg/kg/day 
from 6 days post-infection, inhibited JEV 
replication in vivo 
Mishra et al. 2008 
(Ref. 167) 
Arctigenin 100% of mice protected by 20 mg/kg/day 
from day 1 post-infection. Only used at 
phase I in pancreatic cancer, no data in 
children. 
Swarup et al. 2008 
(Ref. 163) 
Pentoxifylline 50% of mice protected at 100 mg/kg/day 
given immediately after JEV infection, 100% 
protection at >200 mg/kg/day; inhibited JEV 
replication in vitro 
Sebastian et al. 2009 
(Ref. 171) 
Fenofibrate 80% of mice protected by 100 mg/kg/day 
from day 4 pre-infection to day 9 post-
infection 
Sehgal et al. 2012 
(Ref. 168) 
Nitazoxanide 70% of mice protected at 75 mg/kg/day 
from 1 day post-infection, 90% protection at 
100 mg/kg/day; inhibited replication JEV in 
vitro 
Shi et al. 2014 (Ref. 
165) 
Etanercept 80% survival with 100μg etanercept (30% 
without) on days 3 & 5 post-infection, 
reduced CNS inflammation, reduced 
production of inflammatry mediators in vitro 
Ye et al. 2014 (Ref. 
152) 
Compounds with anti-JEV activity in vitro 
Ivermectin Inhibited JE, yellow fever, dengue & West 
Nile virus replication in vitro 
Mastrangelo et al. 
2012 (Ref. 162) 
Niclosamide Inhibited JEV replication in vitro, also 
inhibits Zika virus replication in human 
neural progenitor cells 
Fang et al. 2013 (Ref. 
164) 
Cilnidipine Inhibited JEV replication in vitro, no data in 
children 
Fang et al. 2013 (Ref. 
164) 
Compounds with theoretical activity or indirect evidence 
Eritoran TLR4 antagonist: TLR4 KO reduces JE 
lethality in mice, eritoran protects mice 
against lethal influenza 
 Han et al. (Ref 147)  
Tocilizumab Anti-IL6 antibody: IL6 levels in CSF 
correlate with mortality in JE in humans 
Winter et al. (Ref 151)  
Natalizumab Anti-VLA4 antibody: protective in a mouse 
model of WNV 
Getts et al. (Ref 173)  
PGL5001 c-Jun N terminal kinase (JNK) inhibitor: JNK 
inhibition by a different compound 
protective in a mouse model of JEV 
Ye et al. 2016 (Ref. 
174) 
 
Table 3 | Compounds suitable for human use that have animal model, in vitro, and 
theoretical anti-JEV activity. Compounds with evidence for anti-JEV activity in mouse 
models are shown in the top panel and with anti-JEV activity (inhibition of replication) in cell 
culture are shown in the middle panel. All these compounds except arctigenin and cilnidipine 
have been used in children. Pentoxifylline and nitazoxanide also inhibit JEV replication in 
vitro. Ivermectin inhibits flavivirus NS3 helicase activity162, and inhibited JEV production in 
vitro with EC50 0.3 μM. Niclosamide and cilnidipine inhibited JEV induced cytopathic effect 
and replication164, EC50 5.8 and 6.52 μM, respectively. The bottom panel shows compounds 
with theoretical benefit in Japanese encephalitis. Eritoran (synthetic TLR4 antagonist), 
tocilizumab (anti-IL6 antibody), natalizumab (anti-VLA4 antibody) and PGL5001 (c-Jun N 
terminal kinase (JNK) inhibitor) all have indirect evidence for benefit; their anti-JEV potential 
is hypothetical and requires testing in animal models. 
 
Feature Stage 
V IV III II 
History from child, parents and/or carers 
Speech The same as other 
children of this age  
NA Reduced  Not speaking or 
communicating  
Feeding The same as other 
children  
NA Occasionally 
needs help  
Always needs 
more help  
Can the child be left 
alone? 




Behavior Normal  Gets angry easily, 
other behavioral 
problems  
NA Severely abnormal  
Recognition (other 
than the main carer)  
Too young or yes   Some  None  
School/work, home 
activity if too young  
Back to normal at 
school/work, or if 
too young able to 
do the same tasks 
at home 
Not doing as well, 
not able to do the 
same tasks as 
before 
Dropped a school 
grade, no longer 
attending 
school/work, not 
able to do 
anything at home 
NA 
Seizures in the last 2 
months 
No seizures and 
not on antiepileptic 
drugs 
Seizure free on 
antiepileptic drugs  
Has had seizures  Seizures most 
days  
Ability to dress The same as other 
children the same 
age  
NA Occasionally 
needs extra help 
Always needs 
more help than 
other children of 
the same age  
Urinary and fecal 
continence 
The same as other 
children the same 
age  
NA NA Needs more help 
or is incontinent of 
bowel or bladder  
Hearing Normal  Reduced in one or 
both ears  
Cannot hear at all  NA 
Observation of the child 
Sitting Too young or can 
sit independently  
NA Needs help  Not at all  
Able to move from 
sitting to standing 
Too young or can 
walk 
independently  
NA Needs help  Not at all  
Observe the child 
walking for 5 meters 
Too young or 
normal  
NA Abnormal but 
independent with 
crutches or stick  
Not able to walk  
Put both hands on 
head - ask child to 
copy 
Too young or 
normal with both 
hands  
Abnormal with one 
or both hands  
Unable to put one 
or both hands on 
head 
NA 
Pick up small object Too young or 
normal pincer 
grasp both hands 
NA Unable with one 
hand or abnormal 
with one hand or 
both hands  
Unable both hands 
 
Table 4 | The Liverpool outcome score for assessing outcome from encephalitis. For 
each domain, the child is scored II–V according to residual neurological or behavioral deficits 
as detailed in the table. The final outcome score is the lowest score of any domain; For 
example, if an 8-year old child is normal in every respect other than not being able to be left 
alone, except briefly in a familiar environment, then the outcome score is III. A fatal case has 
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